Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism

Kena C. Miller, Swaminathan Padmanabhan, Laurie Dimicelli, Dawn Depaolo, Beverly Landrigan, Jihnhee Yu, Virginia Doran, Patricia Marshal, Asher A Chanan Khan

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Venous thromboemobolism (VTE) is an important complication of thalidomide therapy especially when it is combined with steroids or chemotherapy. Currently there is no consensus on the most appropriate prophylactic approach. We prospectively investigated the use of low-dose warfarin sodium in prevention of thalidomide-associated VTE in patients receiving thalidomide-based combination therapies. Patients with multiple myeloma or chronic lymphocytic leukemia who were treated on thalidomide based-combination therapies were treated on low-dose warfarin (1 or 2 mg) continuously through the duration of their therapy. Among the 68 patients enrolled, four developed an episode of VTE, an overall incidence of 5.9% (odds = 0.063). Median duration of thalidomide therapy was 4 months. Low-does warfarin decreases the incidence of VTE compared to historical control and is an effective mechanism of prevention of VTE in thalidomide-based chemotherapy regimens.

Original languageEnglish (US)
Pages (from-to)2339-2343
Number of pages5
JournalLeukemia and Lymphoma
Volume47
Issue number11
DOIs
StatePublished - Nov 2006
Externally publishedYes

Fingerprint

Thalidomide
Venous Thromboembolism
Warfarin
Therapeutics
Drug Therapy
Incidence
B-Cell Chronic Lymphocytic Leukemia
Multiple Myeloma
Steroids

Keywords

  • Leukemia
  • Thalidomide
  • Thromboemobolism
  • Warfarin

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. / Miller, Kena C.; Padmanabhan, Swaminathan; Dimicelli, Laurie; Depaolo, Dawn; Landrigan, Beverly; Yu, Jihnhee; Doran, Virginia; Marshal, Patricia; Chanan Khan, Asher A.

In: Leukemia and Lymphoma, Vol. 47, No. 11, 11.2006, p. 2339-2343.

Research output: Contribution to journalArticle

Miller, KC, Padmanabhan, S, Dimicelli, L, Depaolo, D, Landrigan, B, Yu, J, Doran, V, Marshal, P & Chanan Khan, AA 2006, 'Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism', Leukemia and Lymphoma, vol. 47, no. 11, pp. 2339-2343. https://doi.org/10.1080/10428190600799631
Miller, Kena C. ; Padmanabhan, Swaminathan ; Dimicelli, Laurie ; Depaolo, Dawn ; Landrigan, Beverly ; Yu, Jihnhee ; Doran, Virginia ; Marshal, Patricia ; Chanan Khan, Asher A. / Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. In: Leukemia and Lymphoma. 2006 ; Vol. 47, No. 11. pp. 2339-2343.
@article{cd506c17cf8349dab6b4b7a6b63cbcfa,
title = "Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism",
abstract = "Venous thromboemobolism (VTE) is an important complication of thalidomide therapy especially when it is combined with steroids or chemotherapy. Currently there is no consensus on the most appropriate prophylactic approach. We prospectively investigated the use of low-dose warfarin sodium in prevention of thalidomide-associated VTE in patients receiving thalidomide-based combination therapies. Patients with multiple myeloma or chronic lymphocytic leukemia who were treated on thalidomide based-combination therapies were treated on low-dose warfarin (1 or 2 mg) continuously through the duration of their therapy. Among the 68 patients enrolled, four developed an episode of VTE, an overall incidence of 5.9{\%} (odds = 0.063). Median duration of thalidomide therapy was 4 months. Low-does warfarin decreases the incidence of VTE compared to historical control and is an effective mechanism of prevention of VTE in thalidomide-based chemotherapy regimens.",
keywords = "Leukemia, Thalidomide, Thromboemobolism, Warfarin",
author = "Miller, {Kena C.} and Swaminathan Padmanabhan and Laurie Dimicelli and Dawn Depaolo and Beverly Landrigan and Jihnhee Yu and Virginia Doran and Patricia Marshal and {Chanan Khan}, {Asher A}",
year = "2006",
month = "11",
doi = "10.1080/10428190600799631",
language = "English (US)",
volume = "47",
pages = "2339--2343",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism

AU - Miller, Kena C.

AU - Padmanabhan, Swaminathan

AU - Dimicelli, Laurie

AU - Depaolo, Dawn

AU - Landrigan, Beverly

AU - Yu, Jihnhee

AU - Doran, Virginia

AU - Marshal, Patricia

AU - Chanan Khan, Asher A

PY - 2006/11

Y1 - 2006/11

N2 - Venous thromboemobolism (VTE) is an important complication of thalidomide therapy especially when it is combined with steroids or chemotherapy. Currently there is no consensus on the most appropriate prophylactic approach. We prospectively investigated the use of low-dose warfarin sodium in prevention of thalidomide-associated VTE in patients receiving thalidomide-based combination therapies. Patients with multiple myeloma or chronic lymphocytic leukemia who were treated on thalidomide based-combination therapies were treated on low-dose warfarin (1 or 2 mg) continuously through the duration of their therapy. Among the 68 patients enrolled, four developed an episode of VTE, an overall incidence of 5.9% (odds = 0.063). Median duration of thalidomide therapy was 4 months. Low-does warfarin decreases the incidence of VTE compared to historical control and is an effective mechanism of prevention of VTE in thalidomide-based chemotherapy regimens.

AB - Venous thromboemobolism (VTE) is an important complication of thalidomide therapy especially when it is combined with steroids or chemotherapy. Currently there is no consensus on the most appropriate prophylactic approach. We prospectively investigated the use of low-dose warfarin sodium in prevention of thalidomide-associated VTE in patients receiving thalidomide-based combination therapies. Patients with multiple myeloma or chronic lymphocytic leukemia who were treated on thalidomide based-combination therapies were treated on low-dose warfarin (1 or 2 mg) continuously through the duration of their therapy. Among the 68 patients enrolled, four developed an episode of VTE, an overall incidence of 5.9% (odds = 0.063). Median duration of thalidomide therapy was 4 months. Low-does warfarin decreases the incidence of VTE compared to historical control and is an effective mechanism of prevention of VTE in thalidomide-based chemotherapy regimens.

KW - Leukemia

KW - Thalidomide

KW - Thromboemobolism

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=33751103917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751103917&partnerID=8YFLogxK

U2 - 10.1080/10428190600799631

DO - 10.1080/10428190600799631

M3 - Article

C2 - 17107907

AN - SCOPUS:33751103917

VL - 47

SP - 2339

EP - 2343

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 11

ER -